OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP), a biopharmaceutical company making strides in the $7.1 billion prostate cancer treatment space, has continued to show very strong action on the charts so far in 2017, up more than 100% in a little over five weeks of action. We have been closely watching the company this year, and can offer […]